The successful use of the stromal vascular fraction (SVF) cells in these patients shows that further clinical studies should be conducted into the use of SVF cells to treat multiple sclerosis and other autoimmune diseases, the researchers said.
“All three patients in our study showed dramatic improvement in their condition after the course of SVF therapy. While obviously no conclusions in terms of therapeutic efficacy can be drawn from these reports, this first clinical use of fat stem cells for treatment of MS supports further investigation into this very simple and easily-implementable treatment methodology,” Dr. Boris Minev, division of neurosurgery at the University of California, San Diego, said in a news release.
In people with MS, the immune system attacks and destroys the myelin sheath that surrounds and protects nerves cells. It’s believed that SVF cells, and other stem cells, may limit this immune reaction and promote the growth of new myelin.